• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Repare Therapeutics Inc (NQ: RPTX )

    3.750 +0.290 (+8.38%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 142,225
    Open 3.470
    Bid (Size) 3.650 (1)
    Ask (Size) 3.850 (2)
    Prev. Close 3.460
    Today's Range 3.445 - 3.840
    52wk Range 2.710 - 8.840
    Shares Outstanding 42,088,446
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
    From Repare Therapeutics Inc.
    Via Business Wire

    Performance

    YTD
    -48.56%
    -48.56%
    1 Month
    +35.38%
    +35.38%
    3 Month
    +18.30%
    +18.30%
    6 Month
    -5.78%
    -5.78%
    1 Year
    -55.36%
    -55.36%

    More News

    Read More
    Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics to Participate in Two Upcoming Investor Conferences
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
    From Repare Therapeutics Inc.
    Via Business Wire
    Why RingCentral Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    RPTX Stock Earnings: Repare Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
    From Repare Therapeutics Inc.
    Via Business Wire
    Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
    From Debiopharm
    Via Business Wire
    Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
    From Repare Therapeutics Inc.
    Via Business Wire
    Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
    From Repare Therapeutics Inc.
    Via Business Wire
    Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
    Via Benzinga
    Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Repare Therapeutics to Participate in Two Upcoming Investor Conferences
    From Repare Therapeutics Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.